Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
11 févr. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
08 févr. 2016 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
03 févr. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq.,...
Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer
04 janv. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Joel Barrish, Ph.D., has been named the Company’s Chief Scientific Officer...
Achillion Appoints Dr. Frank Verwiel to Board of Directors
16 déc. 2015 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
05 déc. 2015 17h00 HE
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
05 nov. 2015 17h51 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
05 nov. 2015 09h03 HE
|
Achillion Pharmaceuticals, Inc.
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...
Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference
02 nov. 2015 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV
16 oct. 2015 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...